Q&A with Bob Weaver, HunterLab - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Q&A with Bob Weaver, HunterLab
Bob Weaver, president of HunterLab, discusses current trends and challenges.

Pharmaceutical Technology
Volume 35, Issue 4, pp. 87

Q&A with
Bob Weaver, president of HunterLab

Bob Weaver
What is the biggest industry challenge you're now facing?

Product color and appearance are increasingly important, but the pharmaceutical industry is still at an entry level in its integration of color-control instrumentation. Ultraviolet-visible (UV-vis) spectrophotometers are common in most companies. While they technically measure the same spectral range as the human eye, UV-vis spectrophotometers do not correlate with the way it sees color. Application-specific color spectrophotometers are routinely used by the chemical industry for production quality control of fine and specialty chemicals. However, in many pharmaceutical companies, an application-knowledge gap still exists regarding the science of color and appearance. Color-technology awareness and applied solution engineering continue to be at the forefront of our industry focus.

The US Pharmacopeia and the European Pharmacopoeia color standards are commonly used for color specification, but they only cover a small range of the color gamut as seen by the human eye. True, it is easier to add a visual test than to add an analytical-instrument step in the development and production process. However, visual indexing and validation have limitations and are by nature subjective methodology.

Do you see a new industry trend emerging?

Today, consumers equate product quality to an expected appearance. The first things humans notice are a product's size, color, and shape. Color is an important component of branding and recognition. Increasingly, manufacturers are implementing instrumentation to ensure product color quality in many ways. Examples include measuring a lack of color in a liquid or the degree of whiteness of a compound, which correlates to purity or a lack of product degradation. Applications and technology development continue and are extending implementation to the production line.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here